{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/23/3315961/0/en/Quoin-Pharmaceuticals-Receives-FDA-Conditional-Approval-of-QYLEKI-as-the-Proposed-Brand-Name-for-QRX003-for-Netherton-Syndrome.html", "message": "News view counter 811559 successfully enlarged"}